Effect of human flavin-containing monooxygenase 3 polymorphism on the metabolism of aurora kinase inhibitors by Catucci, Gianluca et al.
Int. J. Mol. Sci. 2013, 14, 2707-2716; doi:10.3390/ijms14022707 
 





Effect of Human Flavin-Containing Monooxygenase 3 
Polymorphism on the Metabolism of Aurora Kinase Inhibitors 
Gianluca Catucci, Andrea Occhipinti, Massimo Maffei, Gianfranco Gilardi and  
Sheila J. Sadeghi * 
Department of Life Sciences and Systems Biology, University of Torino, Via Accademia Albertina 13, 
Torino 10123, Italy; E-Mails: gianluca.catucci@unito.it (G.C.); andrea.occhipinti@unito.it (A.O.); 
massimo.maffei@unito.it (M.M.); gianfranco.gilardi@unito.it (G.G.) 
* Author to whom correspondence should be addressed; E-Mail: sheila.sadeghi@unito.it;  
Tel.: +39-011-670-4528; Fax: +39-011-670-4643. 
Received: 9 October 2012; in revised form: 22 December 2012 / Accepted: 18 January 2013 /  
Published: 28 January 2013 
 
Abstract: Aurora kinases were recently identified as a potential target in anticancer 
therapy and, amongst their available inhibitors, Tozasertib (VX-680) and Danusertib  
(PHA-739358) have been indicated as possible substrates of human flavin-containing 
monooxygenase 3 (hFMO3). Here we report the in vitro rate of oxidation of these drugs by 
wild-type hFMO3 and its polymorphic variant V257M. The conversion of Tozasertib and 
Danusertib to their corresponding metabolites, identified by LC-MS, by the purified  
wild-type and V257M hFMO3 show significant differences. In the case of Tozasertib, the 
V257M variant shows a catalytic efficiency, expressed as kcat/Km, similar to the wild-type: 
0.39 ± 0.06 min−1µM−1 for V257M compared to 0.33 ± 0.04 min−1µM−1 for the wild type. 
On the other hand, in the case of Danusertib, V257M shows a 3.4× decrease in  
catalytic efficiency with kcat/Km values of 0.05 ± 0.01 min−1µM−1 for V257M and  
0.17 ± 0.03 min−1µM−1 for the wild type. These data reveal how a simple V257M 
substitution ascribed to a single nucleotide polymorphism affects the N-oxidation of 
relevant anticancer drugs, with important outcome in their therapeutic effects. These 
findings demonstrate that codon 257 is important for activity of the hFMO3 gene and the 
codon change V to M has an effect on the catalytic efficiency of this enzyme. 








Human flavin-containing monooxygenase 3 (hFMO3) is the second most important Phase I drug 
metabolising enzyme after cytochromes P450. It is expressed in the adult human liver where it 
catalyses the NADPH-dependent N- and S-oxidation of drugs and xenobiotics [1]. Previously it has 
been reported that there is a 10- to 20-fold inter-individual difference in FMO expression that may 
contribute to drug response [2–4]. Furthermore, the existence of polymorphisms affecting  
hFMO3-dependent metabolism has also been documented [5], with several studies showing reduced 
activity with some common variants. 
Several polymorphic variants of hFMO3 have been identified among which V257M (rs2266782), 
E158K (rs2266780), and E308G (rs1736557) are the most commonly distributed. Inter-individual and 
inter-ethnic variability in hFMO3 expression and enzyme activity is primarily due to genetics, 
therefore, making it possible to correlate hFMO3 allelic variants to drug-induced side effects or drug 
response. It has been previously shown that minor allele frequencies of E158K, V257M, and E308G 
vary greatly among different ethnic populations with distinct genetic backgrounds [6]. Moreover, 
allelic variation within the hFMO3 gene can also influence a person’s drug responsiveness [7] with 
important differences in the therapeutic response of life-saving drugs such as anticancer drugs. 
Aurora A, Aurora B, and Aurora C are serine-threonine kinases that regulate mitotic events. The 
first two are the best studied and were assigned different roles in mitosis [8]: Aurora A was found to be 
over-expressed in many human tumors like breast, colorectal, and ovarian cancer [8], and Aurora B is 
also over-expressed in various types of cancer [9,10]. Specific inhibitors of Aurora kinases, such as 
VX-680, MLN8054, AZD1152, R766, R763, and PHA-739358, have been designed and screened for 
their inhibitory activity in cancer events [11].  
The VX-680 inhibitor, also known as Tozasertib, was originally discovered by Harrington and  
co-workers [12], and it is an inhibitor of Aurora-A, Aurora-B, and Aurora-C kinases with inhibition 
constants (Kiapp) of 0.6, 18 and 4.6 nM, respectively [12,13].  
Rational design of the pyrrolopyrazole identified from the combinatorial expansion of the  
1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles bound to the pocket of the target led to the discovery of the 
PHA-739358 inhibitor, also called Danusertib [14,15]. This compound was also found to inhibit 
several tyrosine kinases such as Abl, Ret, Trk-A, and FGFR-1 that are involved in many types of 
cancer such as leukemia, thyroid, prostate, and breast carcinoma [14,15]. 
Tozasertib is metabolised into the N-desmethyl product by CYP3A4 and CYP2C8, and into the  
N-oxide product by CYP3A4 and hFMO3, as previously demonstrated by Ballard and co-workers [16]. 
Their study highlighted the combined contribution of hFMO3 and P450 3A4 to the formation of the  
N-oxide metabolite in human liver microsomes. 
Knowledge of genetic polymorphism and its possible related functional changes is increasingly 
considered critical for both drug discovery and drug development [17,18]. Since Tozasertib and 
Danusertib have been indicated as substrates of the drug metabolizing flavin-containing 
monooxygenases, in this work we measure the kinetic parameters of the wild type hFMO3 (WT) and 
V257M polymorphic variant with these Aurora kinase inhibitors. 
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2. Results and Discussion 
In order to determine the kinetic parameters related to the metabolism of Tozasertib and Danusertib 
by hFMO3, both WT and the V257M polymorphic variant were heterologously expressed in 
Echerichia coli and purified as previously described [19–22]. Both proteins showed a single band on 
SDS-PAGE gel with a yield of around 12 mg of protein per litre of culture. A molar ratio of more than 
91% holo protein was determined spectrophotometrically [21] for both proteins. Positive control 
reactions, with benzydamine and methimazole as substrates, were performed to confirm the catalytic 
activities of the enzyme preparations. 
We have chosen the V257M and not the other two common SNPs (single nucleotide 
polymorphism) due to the fact that residue 257 is located in the “insert” region of the hFMO3 gene 
which is absent in the bacteria and yeast FMO amino acid sequences [23]. As a consequence, this 
“insert” region is not present in the two published crystal structures of FMO and, therefore, the exact 
location of this amino acid in relation to the active site of this enzyme can only be hinted at by ab initio 
modeling. We have previously generated a model of hFMO3 [19], however in our model the location 
of residue 257 is not very close to the FAD catalytic center, similar to the modeling results of Rettie 
and colleagues [23].  
In a previous study we had shown the turnover of the WT hFOM3 in the presence of both 
Danusertib and Tozasertib using HPLC analysis [21]. In the current report, the metabolites of the 
enzymatic reaction of both WT and V257M polymorphic variant with Danusertib and Tozasertib were 
identified by LC-MS. In each case, the occurrence of the enzymatic oxidative reaction was confirmed 
by the molecular shift of 16 atomic mass units (amu) of both substrates. The oxidation  
sites were confirmed through comparison with LC-MS fragmentation profiles of substrates and  
observed metabolites.  
2.1. Tozasertib Metabolism by hFMO3 
In 2007, Ballard and co-workers [16] identified the metabolites of Tozasertib generated in human 
hepatocytes that were mainly the N-oxide and the desmethyl products. They went on to characterize 
the hepatic enzymes responsible and found that hFMO3 appreciably (50%–60%) contributed to the  
N-oxidation of Tozasertib in human liver microsomes together with cytochrome P450 3A4. Following 
in their footsteps, we investigated the metabolism of Tozasertib using the purified WT hFMO3, and 
identified the metabolite by LC-MS. The suggested fragmentation profile of Tozasertib (Figure 1A) 
includes the molecular ion [M + H]+ 465.2 and subsequent 397.2 and 340.0 in MS(3) as cleavage of 
C4O group and pyridine ring, respectively. On the other hand, Tozasertib-N-oxide fragmentation 
(Figure 1B) shows the molecular ion [M + H]+ 481.2, the cleavage of N-oxide pyridine ring (394.1) 
first and the cleavage of C4O in the last fragmentation step.  
The same enzymatic reactions followed by LC-MS analyses were carried out for the V257M 
polymorphic variant in order to test whether the variant was not only capable of metabolising 
Tozasertib, but also resulted in the same N-oxide metabolite. 
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Figure 1. (a) Fragmentation profile of Tozasertib showing the molecular ion [M + H]+ 
465.2 and subsequent 397.2 and 340.0 in MS(3) as cleavage of C4O group and pyridine 
ring, respectively; (b) Tozasertib-N-oxide fragmentation showing the molecular ion  
[M + H]+ 481.2, the cleavage of N-oxide pyridine ring (394.1) first and the cleavage of 
C4O in the last fragmentation step. 
 
2.2. Danusertib Metabolism by hFMO3 
The major route of Danusertib metabolism involves the formation of N-oxide product by the action 
of hFMO3 forming an inactive metabolite. A possible influence of a SNP in the hFMO3 gene, on the 
metabolism of Danusertib, was proposed by Steeghs and co-workers in 2010 [24] when they showed a 
different clearance of the drug from the body in a patient heterozygous for V257M. Since the latter 
correlation between Danusertib pharmacokinetics and genetic variation was based on the data from a 
single patient, we thought the role of V257M in the metabolism of Danusertib warranted further 
investigation and decided to check the kinetics of Danusertib metabolism with the purified hFMO3 
V257M polymorphic variant. To this end, initially in vitro experiments were set up for the 
identification of the N-oxide product by LC-MS and subsequently followed by the determination of the 
kinetic parameters of the enzymatic reactions. 
For the LC-MS experiments, purified WT and V257M hFMO3 were incubated with NADPH and 
Danusertib and the enzymatic reaction terminated after 10 min, and the resulting metabolites identified 
as described in the experimental section. Mass spectrometry analysis for Danusertib and its N-oxide 
showed, at the first fragmentation step, the loss of the common methoxy group [M-CH3OH]+  
(443.2 and 459.2 for Danusertib and its N-oxide). Their MS(2) fragmentation generates ion 203.0 for 
Danusertib and the 16 amu-shifted fragment at 219.0 for the N-oxide product (Figure 2A,B). 
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Moreover, the latter showed a fragmentation ion from N-oxide pyridine ring at 160.0 that limits the  
N-oxidation site to the quaternary amine on the pyridine ring.  
Figure 2. (a) Fragmentation profile of Danusertib showing the molecular ion [M + H]+ 
475.2 and subsequent 443.2 as loss of the common methoxy group [M-CH3OH]+ at the first 
fragmentation step; (b) Fragmentation profile of Danusertib N-oxide showing the 
molecular ion [M + H]+ 459.2 as loss of the common methoxy group [M-CH3OH]+ at the 
first fragmentation step. 
 
2.3. Kinetic Measurements of hFMO3 with Aurora Kinase Inhibitors 
Enzymatic reactions were carried out with the purified WT and V257M polymorphic variant in the 
presence of NADPH and increasing amounts of each substrate as reported in the experimental section. 
Kinetic parameters for N-oxygenation of Tozasertib were determined by nonlinear regression analysis 
and showed a Km of 23.8 µM, a kcat of 9.3 min−1 in the case of the wild-type enzyme and a Km value of 
12.9 µM, a kcat of 4.3 min−1 for the polymorphic variant V257M. The kcat and Km values for V257M 
were approximately half of that of the wild-type (Figure 3A,B) and the kcat for the wild-type enzyme 
was at least twice as much of the kcat for V257M. When the ratios of kcat/Km are compared, both 
enzymes seem to be equally efficient in transforming Tozasertib into the N-oxide product. The  
Km values measured are slightly higher when compared to the data published by Ballard and  
co-workers [16], probably because they specifically address the substrate binding to hFMO3 and do 
not consider the role of cytochrome P450 3A4 that also contributes to the overall N-oxide metabolite 
of Tozasertib. Moreover, for Tozasertib the Vmax of wild type hFMO3 was 536 pmol/min/mg FMO3 
while V257M hFMO3 Vmax resulted in 248 pmol/min/mg FMO3 (Table 1) in good agreement with the 
data published by Ballard and co-workers [16].  
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Figure 3. (a) Michaelis-Menten kinetics for the formation of the N-oxide metabolite of 
Tozasertib and Danusertib with wild type (A and C, respectively), and V257M (B and D, 
respectively) hFMO3. Reactions were carried out with 0.17 µM of each purified enzyme in 
50 mM potassium phosphate buffer pH 7.4 and 0.5 mM NADPH in the presence of 
increasing amounts of Tozasertib (0–300 µM) and Danusertib (0–200 µM), at 37 °C  
for 10–15 min. 
 
Kinetic parameters for N-oxygenation of Danusertib were also determined by nonlinear regression 
analysis, and showed a Km of 57.3 µM, a Vmax of 0.57 nmol min−1 mg FMO3, and kcat of 9.9 min−1 for 
the wild-type enzyme and a Km of 60.1 µM, a Vmax of 0.18 nmol min−1 mg FMO3 and kcat of 3.2 min−1 
for V257M (Figure 3C,D). The Km value for the polymorphic variant V257M was very similar to that 
of the wild-type indicating that Danusertib binding is similar in the two proteins. More interestingly 
the Vmax in the case of V257M was approximately three times less than the wild-type (Table 1), 
showing a decreased turnover rate that yields a significantly lower turnover number. The kcat/Km ratio 
is three times higher for the wild type hFMO3, which means that the variant V257M is less efficient in 
metabolizing Danusertib.  
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Table 1. Kinetic analysis of Tozasertib and Danusertib metabolism by WT and V257M 
polymorphic variant of hFMO3. 
 WT hFMO3 V257M hFMO3 
 Km Vmax kcat kcat/Km Km Vmax kcat kcat/Km 
 µM nmol/min/mg FMO3 min−1 min−1 µM−1 µM nmol/min/mg FMO3 nmol/min/mg FMO3 min−1 µM−1 
Tozasertib 23.8 ± 3.4 0.54 ± 0.02 9.3 ± 0.3 0.39 ± 0.06 12.9 ± 1.3 0.25 ± 0.01 4.3 ± 0.1 0.33 ± 0.04 
Danusertib 57.3 ± 8.3 0.57 ± 0.03 9.9 ± 0.6 0.17 ± 0.03 60.1 ± 11.4 0.18 ± 0.01 3.2 ± 0.3 0.05 ± 0.01 
3. Experimental Section  
3.1. Reagents 
FAD, acetonitrile, methanol, NADPH, Verapamil and salts were purchased from Sigma-Aldrich 
(Milan, Italy). VX-680 and PHA-739358 were purchased from Aurogene (Rome, Italy). 
3.2. Recombinant FMO3 Protein Preparation 
WT hFMO3 was cloned in the expression vector pJL2 using the two restriction enzymes, XbaI and 
HindIII, as previously reported [19,21]. QuikChange Site-Directed Mutagenesis Kit (Stratagene, 
Torino, Italy) was used to obtain the V257M polymorphic variant using the following two primers 
(mutation site in bold): 
5' CT GAC TGG TTG TAC ATG AAG CAG ATG AAT GC 3' 
5' GC ATT CAT CTG CTT CAT GTA CAA CCA GTC AG 3' 
Subsequently the presence of the correct mutation was confirmed by sequencing the entire clone. 
Wild type and V257M hFMO3 were heterologously expressed in E. coli JM109 cells and grown 24 h 
post-induction. Both proteins were purified from the membrane fractions using Ni affinity 
chromatography. Spectra of the fractions eluted with 40 mM histidine were recorded using a diode 
array HP-8453E spectrophotometer. FAD-containing fractions with the characteristic absorption peaks 
at 375 and 442 nm were pooled and exchanged with storage buffer (100 mM potassium phosphate 
buffer pH 7.4, 20% glycerol and 1 mM EDTA) by 30 kDa cutoff Amicon membranes (Millipore, 
Billercia, MA, USA) and stored at −20 °C. 
The concentration of hFMO3 was determined by spectroscopy with the peak absorbance at 450 nm 
and an extinction coefficient of 11900 M−1 cm−1. This value was also used for determination of the 
enzyme concentration under non-denaturing conditions. The yield of the purified hFMO3 protein was 
determined using both absorbance at 280 nm (calculated extinction coefficient of 87520 M−1 cm−1) and 
Bradford assay. 
3.3. Enzyme Assays 
N-oxygenation of Tozasertib and Danusertib was evaluated by incubating a mixture of 0.17 µM of 
purified enzyme in 50 mM potassium phosphate buffer (pH 7.4), 0.5 mM NADPH, and increasing 
amounts of substrate in a final volume of 0.20 mL. The enzyme and NADPH were mixed first and the 
reaction was initiated by the addition of substrate, preventing thermal degradation of the enzyme. 
Incubations were carried out at 37 °C for 10 min in the case of Danusertib, and 15 min in the case of 
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Tozasertib: the linearity of product formation was confirmed with purified hFMO3 preparations for  
20 min. The incubations were terminated by the addition of 0.10 mL of ice-cold methanol and 150 µL 
verapamil as internal standard (IS). 
3.4. LC-MS Analyses of Danusertib, Tozasertib and Corresponding N-oxides 
Prior to LC-MS analysis the reaction mixtures were filtered through a Microcon centrifugal 
membrane with 3 kDa cutoff (Millipore, Billercia, MA, USA). Substrates and their metabolites were 
separated using Agilent 1200 HPLC (Agilent Technologies Inc., Santa Clara, CA, USA) equipped with 
a narrow bore reversed-phase column Zorbax Eclipse XDB-C18, 2.1 × 150 mm, 3.5 μm (Agilent 
Technologies, Santa Clara, CA, USA) and using a binary solvent system composed of double distilled 
water with 0.01% formic acid (A), and acetonitrile (ACN) with 0.1% formic acid (B) at flow rate of  
0.2 mL min−1. The initial mobile phase was composed of 20% of solvent B and it was increased to 
70% over a period of 3 min and kept 4 min for isocratic separations of substrate, metabolite and 
internal standard (IS). Finally, the organic solvent was increased to 100% in 30 s for washing the 
column. Before follower injection, initial mobile phase was re-established for 10 min. 
Prior to MS detection, the column eluate was monitored on-line with UV detection at 250 nm 
wavelength for substrates and their metabolites, and 280 nm for IS. The MS analyses were made by a 
6330 Series Ion Trap Mass Spectrometer (Bruker Daltonik GmbH, Bremen, Germany) equipped with 
an electrospray ionization source.  
Analyses for fragmentation spectra were conducted by ESI-MS/MS operating in full scan from  
50 to 900 m/z. Spectra were acquired in positive mode with ion spray voltage at 1.2 kV, nebulizer gas 
(N2) at 15 psi and 5 L min−1, dry temperature at 325 °C, and 1.00 V fragmentation amplitude.  
For quantitative purpose, standards and samples were analysed by LC-ESI-MS/MS in MRM mode 
using the above-indicated parameters. The monitored mass transitions were m/s 465.2→408.1, 
481.2→437.1, 475.2→443.2, 491.2→459.2 and 455.3→303.1 for Tozasertib, Tozasertib-N-oxide, 
Danusertib, Danusertib-N-oxide and Verapamil, respectively. Spectral data were processed using data 
analysis software of 6300 Series Ion Trap LC/MS 4.0 (Bruker Daltonik GmbH, Bremen, Germany). 
Metabolite formation was quantified by comparing peak area ratios (metabolite/internal standard) of 
four data sets of incubations for each Michaelis-Menten curve to ratios obtained from a standard curve 
containing known amounts of the internal standard verapamil. 
4. Conclusions 
In conclusion, Tozasertib is metabolised by hFMO3 to the expected N-oxide. The V257M 
polymorphic variant displays little difference in the N-oxidation of this drug, so since cytochrome 
P450 3A4 and hFMO3 appear to be important in the latter reaction [16] the inter-individual variations 
related to the metabolism of this drug can only be due to genetic or environmental factors influencing 
the activity of cytochrome P450 3A4. On the other hand, Danusertib is also metabolised by hFMO3 to 
the corresponding N-oxide, but its metabolism is markedly influenced by the V257M polymorphism 
showing a 3.4 times lower catalytic efficiency compared to the wild type enzyme implying that  
inter-individual variations of the hFMO3 gene can result in decreased activity towards this drug.  
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Finally, the V257M substitution of hFMO3 represents a good example of how this SNP can 
influence the N-oxidation of relevant anticancer drugs. These findings demonstrate the need for  
further research into the consequences of flavin-containing monooxygenase genetic polymorphism in  
drug metabolism. 
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